Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Completed · Phase 2
Conditions studied: Leukemia
In brief
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).
Key facts
- Study ID
- NCT00782067
- Run by
- Novartis Pharmaceuticals
- People needed
- 116
- Starts
- 2008-10-13
- Expected to finish
- 2017-08-24
- Last updated by the study team
- 2018-11-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California at Los Angeles Dept. of Hematology Clinic — Los Angeles, California, United States
- Stanford University Medical Center Stanford University 2 — Stanford, California, United States
- Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia — Augusta, Georgia, United States
- Dana Farber Cancer Institute Hematology / Oncology — Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(3) — Ann Arbor, Michigan, United States
- Memorial Sloan Kettering Cancer Center Dept. of MSKCC (2) — New York, New York, United States
- Oregon Health and Science University Dept. Hematologic Malignancies — Portland, Oregon, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Virginia Commonwealth University SC — Richmond, Virginia, United States
- Novartis Investigative Site — Camperdown, New South Wales, Australia
- Novartis Investigative Site — Prahran, Victoria, Australia
- Novartis Investigative Site — Vienna, Austria
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — London, Ontario, Canada
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Amiens, France
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Mannheim, Baden-Wurttemberg, Germany
- Novartis Investigative Site — Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Leipzig, Germany
- Novartis Investigative Site — Groningen, Netherlands
- Novartis Investigative Site — Oslo, Norway
- Novartis Investigative Site — Gdansk, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.